Related Experiment Videos
Isoniazid therapy in Parkinson's disease
O S Gershanik1, M R Luquin, O Scipioni
1Centro Neurológico, Hospital Francés, Buenos Aires, Argentina.
Summary
Isoniazid significantly reduced levodopa-induced dyskinesias in Parkinson's disease patients but worsened parkinsonian symptoms. This drug interaction highlights isoniazid's interference with levodopa and dopamine agonist therapies.
Area of Science:
- Neurology
- Pharmacology
Background:
- Parkinson's disease is characterized by motor symptoms and often treated with levodopa.
- Levodopa therapy can induce dyskinesias, involuntary movements that impair quality of life.
- Isoniazid is a primary treatment for tuberculous infections.
Purpose of the Study:
- To evaluate the effect of isoniazid on levodopa-induced dyskinesias in Parkinson's disease patients.
- To investigate the potential therapeutic benefits and drawbacks of isoniazid in this context.
Main Methods:
- A study involving 20 Parkinson's disease patients experiencing levodopa-induced dyskinesias.
- Administration of a mean dose of 290 mg of isoniazid without altering existing antiparkinsonian treatments.
- Observation of changes in dyskinesia severity and parkinsonian motor signs.
Main Results:
- Marked reduction in choreic dyskinesias in 18 out of 20 patients within weeks of initiating isoniazid.
- Significant worsening of parkinsonian signs observed concurrently with dyskinesia reduction.
- Patients reverted to their baseline condition upon discontinuation of isoniazid.
Conclusions:
- Isoniazid effectively reduces levodopa-induced dyskinesias in Parkinson's disease.
- However, isoniazid interferes with the therapeutic efficacy of levodopa and dopamine agonists, worsening parkinsonian symptoms.
- The precise mechanism of this interaction requires further investigation.